| RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers. RJ Nichols, F Haderk, C Stahlhut, CJ Schulze, G Hemmati, D Wildes, ... Nature cell biology, 2018 | 325 | 2018 |
| The role of microRNAs in cancer CE Stahlhut Espinosa, FJ Slack Yale J Biol Med 79 (3-4), 131-140, 2006 | 265* | 2006 |
| A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer AL Kasinski, K Kelnar, C Stahlhut, E Orellana, J Zhao, E Shimer, S Dysart, ... Oncogene 34 (27), 3547, 2015 | 236 | 2015 |
| MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications C Stahlhut, FJ Slack Genome medicine 5 (12), 111, 2013 | 197 | 2013 |
| Zebrafish miR-1 and miR-133 shape muscle gene expression and regulate sarcomeric actin organization Y Mishima, C Abreu-Goodger, AA Staton, C Stahlhut, C Shou, C Cheng, ... Genes & development 23 (5), 619-632, 2009 | 183 | 2009 |
| Combinatorial action of MicroRNAs let-7 and miR-34 effectively synergizes with erlotinib to suppress non-small cell lung cancer cell proliferation C Stahlhut, FJ Slack Cell Cycle 14 (13), 2171-2180, 2015 | 161 | 2015 |
| The let-7 microRNA target gene, Mlin41/Trim71 is required for mouse embryonic survival and neural tube closure B R. Maller Schulman, X Liang, C Stahlhut, C DelConte, G Stefani, ... Cell Cycle 7 (24), 3935-3942, 2008 | 151 | 2008 |
| miR-1 and miR-206 regulate angiogenesis by modulating VegfA expression in zebrafish C Stahlhut, Y Suárez, J Lu, Y Mishima, AJ Giraldez Development 139 (23), 4356-4365, 2012 | 122 | 2012 |
| miR-1-2 gets to the heart of the matter Y Mishima, C Stahlhut, AJ Giraldez Cell 129 (2), 247-249, 2007 | 61 | 2007 |
| The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein M Chen, DG Nowak, N Narula, B Robinson, K Watrud, A Ambrico, ... J Cell Biol, jcb. 201604025, 2017 | 43 | 2017 |
| Targeted resequencing of the microRNAome and 3′ UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer X Chen, T Paranjape, C Stahlhut, T McVeigh, F Keane, S Nallur, N Miller, ... Oncogene 34 (16), 2125-2137, 2015 | 27 | 2015 |
| Rapid in vivo validation of candidate drivers derived from the PTEN-mutant prostate metastasis genome H Cho, T Herzka, C Stahlhut, K Watrud, BD Robinson, LC Trotman Methods 77, 197-204, 2015 | 14 | 2015 |
| Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, RAS-GTP dependent oncogenic BRAF and NF1 loss RJ Nichols, F Haderk, C Stahlhut, CJ Schulze, G Hemmati, D Wildes, ... bioRxiv, 188730, 2017 | 13 | 2017 |
| Allosteric inhibition of SHP2 variants containing cancer-associated activating mutations D Wildes, N Aay, A Buckl, D Hsieh, AS Jogalekar, G Kiss, ES Koltun, ... Cancer Research 78 (13 Supplement), 4877-4877, 2018 | 2 | 2018 |
| Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, NF1 loss and RAS-GTP-dependent oncogenic BRAF TG Bivona, R Nichols, F Haderk, C Stahlhut, C Schulze, G Hemmati, ... Cancer Research 78 (13 Supplement), 3993-3993, 2018 | | 2018 |
| Myc vs. Akt therapy in RapidCap, a GEM model for metastatic prostate cancer CE Stahlhut, AJ Ambrico, KE Watrud, H Cho, L Wang, J Qi, LC Cantley, ... Cancer Research 76 (14 Supplement), 4165-4165, 2016 | | 2016 |
| Myc vs. Akt therapy in RapidCap, a GEM model for metastatic prostate cancer CE Stahlhut, KE Watrud, AJ Ambrico, H Cho, L Wang, J Qi, LC Cantley, ... Cancer Research 75 (15 Supplement), 2636-2636, 2015 | | 2015 |
| The microRNAs miR-1 and miR-206 regulate angiogenesis by targeting the vascular endothelial growth factor-A (vegf-a) CE Stahlhut YALE UNIVERSITY, 2011 | | 2011 |
